This report suggests that the surveillance of relatives with RET gene variants in cases of MTC and the approach to suspected MTC/MEN2A in RET gene carriers with F-HSCR may need to be reconsidered. This evidence concerns the gene RET and medullary thyroid gland carcinoma.